Xencor | XNCR - Cash And Equivalent

Stock Price
8.41
Daily Change
-0.14 -1.64%
Monthly
20.14%
Yearly
-57.72%
Q3 Forecast
8.48

Xencor reported $44.44M in Cash and Equivalent for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 879.42M
Cash and Equivalent USD 44.44M
Cost of Sales USD 61.66M
Current Assets USD 513.15M
Current Liabilities USD 96.08M
Debt USD 67.93M
EBIT USD -22.83M
EBITDA USD -30.52M
Employees 250
EPS Earnings Per Share USD -0.41
Equity Capital and Reserves USD 620.35M
Gross Profit on Sales USD 43.61M
Interest Expense on Debt USD 8.24M
Interest Income USD 7.25M
Loan Capital USD 94.74M
Market Capitalization USD 522.6M
Net Income USD -30.83M
Operating Expenses USD 76.78M
Operating Profit USD -33.17M
Ordinary Share Capital USD 71.3M
PE Price to Earnings USD 29.92
Pre-Tax Profit USD -31.08M
Sales Revenues USD 43.61M
Selling and Administration Expenses USD 15.12M
Stock USD 0
Trade Creditors USD 18.53M
Trade Debtors USD 47.55M

Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Arrowhead Research USD 129.79M 55.92M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Cytokinetics USD 74.94M 863.28M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
MacroGenics USD 130.69M 52.15M Jun/2025
Merck USD 8.01B 622M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Xencor USD 44.44M 4.77M Jun/2025